全文获取类型
收费全文 | 575篇 |
免费 | 31篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 18篇 |
口腔科学 | 29篇 |
临床医学 | 25篇 |
内科学 | 29篇 |
皮肤病学 | 4篇 |
神经病学 | 5篇 |
特种医学 | 12篇 |
外科学 | 33篇 |
综合类 | 151篇 |
预防医学 | 7篇 |
眼科学 | 5篇 |
药学 | 52篇 |
中国医学 | 253篇 |
肿瘤学 | 4篇 |
出版年
2024年 | 4篇 |
2022年 | 10篇 |
2021年 | 27篇 |
2020年 | 37篇 |
2019年 | 46篇 |
2018年 | 38篇 |
2017年 | 12篇 |
2016年 | 10篇 |
2015年 | 10篇 |
2014年 | 25篇 |
2013年 | 14篇 |
2012年 | 39篇 |
2011年 | 33篇 |
2010年 | 45篇 |
2009年 | 20篇 |
2008年 | 15篇 |
2007年 | 27篇 |
2006年 | 21篇 |
2005年 | 16篇 |
2004年 | 21篇 |
2003年 | 19篇 |
2002年 | 15篇 |
2001年 | 35篇 |
2000年 | 12篇 |
1999年 | 19篇 |
1998年 | 10篇 |
1997年 | 8篇 |
1996年 | 10篇 |
1995年 | 8篇 |
1994年 | 5篇 |
1993年 | 8篇 |
1992年 | 2篇 |
1991年 | 4篇 |
1990年 | 2篇 |
1987年 | 2篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有633条查询结果,搜索用时 15 毫秒
101.
102.
Xin-Wei He Yan-Hui Shi Rong Zhao Yi-Sheng Liu Ge-Fei Li Yue Hu Wei Chen Guo-Hong Cui Jing-Jing Su Jian-Ren Liu 《Journal of stroke and cerebrovascular diseases》2019,28(6):1654-1661
Introduction: Multiple microRNAs (miRNAs) participate in the response to hypoxic/ischemic and ischemia-reperfusion events. However, the expression of these miRNAs in circulation from patients with acute ischemic stroke (AIS) receiving recanalization treatment has not been examined, and whether they are associated with the severity and outcome of stroke is still unknown. Materials and methods: In this prospective cohort study, plasma levels of miR-125b-5p, miR-15a-3p, miR-15a-5p, and miR-206 were measured at 24 hours after thrombolysis with or without endovascular treatment in 94 patients with AIS, as determined by qRT-PCR. Stroke severity was assessed based on National Institutes of Health Stroke Scale (NIHSS) score and infarct lesion. Intracranial haemorrhage (ICH) was recorded. An unfavorable outcome was defined as a modified Rankin Scale score greater than 2 at day 90 after stroke. Results: miR-125b-5p and miR-206 levels were correlated with NIHSS scores (P = .014 and P = .002) and cerebral infarction volumes (P = .025 and P = .030). miR-125b-5p levels were significantly higher in patients with an unfavorable outcome than in patients with a favorable outcome (P = .002) and showed good diagnostic accuracy in discriminating the presence of an unfavorable outcome (area under the curve .735, 95% confidence interval .623-.829, P < .001). No association was found between different miRNAs and ICH. Conclusions: In AIS patients after thrombolysis with or without endovascular treatment, miR-125b-5p is a novel prognostic biomarker highly associated with an unfavorable outcome. miR-125b-5p and miR-206 levels are associated with stroke severity. 相似文献
103.
Ying Yan Xiaoni Lv Jun Ma Ganji Hong Shikai Li Jiahao Shen Haotian Chen Kailei Cao Senjiang Chen Tao Cheng Chaojie Dong Jiahui Han Heng Ma Mingkang Wu Xin Wang Chenkai Xing Yutao Zhu Lanyu Shen Zhongchao Wang 《Transplantation proceedings》2019,51(8):2798-2807
PurposeThe objective of this research was to survey the therapeutic action of simvastatin (Sim) on intestinal ischemia/reperfusion injury (II/RI) by modulating Omi/HtrA2 signaling pathways.MethodsSprague Dawley rats were pretreated with 40 mg/kg Sim and then subjected to 1 hour of ischemia and 3 hours of reperfusion. The blood and intestinal tissues were collected, pathologic injury was observed, the contents of serum tumor necrosis factor-α and interleukin–6 (IL–6) were estimated, and superoxide dismutase, methane dicarboxylic aldehyde, and cysteinyl aspartate specific proteinase–3 (caspase–3) levels, as well as the expressions of Omi/HtrA2 and caspase–3, were measured in the intestinal tissues.ResultsSim preconditioning mitigated the damnification of intestinal tissues by decreasing oxidative stress, inflammatory damage, and apoptosis and downregulating the expression of Omi/HtrA2 compared to the ischemia/reperfusion group, while Sim+Ucf–101 significantly augmented this effect.ConclusionThese results suggest that Sim may alleviate intestinal ischemia/reperfusion injury by modulating Omi/HtrA2 signaling pathways. 相似文献
104.
105.
Yueping Jin Hui Dong Liliang Xia Yi Yang Yongqiang Zhu Yan Shen Huajun Zheng Chengcheng Yao Ying Wang Shun Lu 《Journal of thoracic oncology》2019,14(8):1378-1389
IntroductionGut microbiome affecting the responses to immune checkpoint inhibitors against advanced NSCLC has been investigated in the Western population. However, considering pre-existing genetic and gut microbiota variation, the relevance remains unknown in the East-Asian NSCLC population. This study is designed to explore the relationship between gut microbiome and clinical outcomes in Chinese patients with NSCLC who have received treatment using an anti–programmed death 1 (PD-1) blockade.MethodsThirty-seven patients with advanced NSCLC receiving treatment with nivolumab were enrolled in CheckMate 078 (NCT02613507) and CheckMate 870 (NCT03195491). Fecal samples were collected at the starting point, when patients received nivolumab, at clinical evaluation, and when disease progression was noted. 16S ribosome RNA gene sequencing was applied to assess gut microbiota profiles. Peripheral immune signatures were determined by multicolor flow cytometry in parallel.ResultsWhen subgrouping patients into responder (R) and nonresponder according to the clinical response assessed using Response Evaluation Criteria in Solid Tumor version 1.1, R patients harbored higher diversity of gut microbiome at the starting point with stable composition during the treatment. Patients with high microbiome diversity had significantly prolonged progression-free survival when compared to those with low diversity. Compositional difference was observed between the two groups as well with the enrichment of Alistipes putredinis, Bifidobacterium longum, and Prevotella copri in R whereas Ruminococcus_unclassified enriched in nonresponding patients. Analysis of systemic immune responses using multicolor flow cytometry revealed that patients with a high abundance of microbiome diversity in the gut had a greater frequency of unique memory CD8+ T cell and natural killer cell subsets in the periphery in response to anti–PD-1 therapy.ConclusionsOur results reveal strong correlation between gut microbiome diversity and the responses to anti–PD-1 immunotherapy in Chinese patients with advanced NSCLC. Patients with favorable gut microbiome (such as those with high diversity) exhibit enhanced memory T cell and natural killer cell signatures in the periphery. These findings provide important implications for the prediction and the evaluation of anti–PD-1 immunotherapy against NSCLC in the Chinese population. 相似文献
106.
BackgroundThis study intended to investigate the optimal surgical strategy in hallux valgus (HV), and to provide a basis for clinical treatment of HV.MethodsStudies related to chevron osteotomy and scarf osteotomy for HV were enrolled from online databases. Hallux valgus angle (HVA) was the main outcome variable. Enrolled studies included posttreatment data for intermetatarsal angle (IMA), American Orthopaedic Foot & Ankle Society (AOFAS) score, and complications. A random-effects model was applied for significant heterogeneity. Otherwise, a fixed-effects model was used. Heterogeneity was assessed with Q test and I2 statistics. Publication bias was evaluated with Egger's test. Based on the influence of weighted mean difference values or odds ratios, a sensitivity analysis was performed.ResultsFour studies including 384 subjects were evaluated to determine the optimal surgical strategy for HV. There was no statistically significant difference between chevron and scarf groups for HVA, IMA, AOFAS score, and complication rates. Sensitivity analysis showed good stability. The likelihood of publication bias was small.ConclusionThe effects of chevron osteotomy and scarf osteotomy for HV are comparable. Chevron osteotomy is less technically demanding. 相似文献
107.
目的通心络对急性脑梗死治疗作用的基础和临床研究。方法135例患者随机分成治疗组和对照组。治疗前后查Tin、t—PA、PAl、AⅢ、ACA、D—dinaer、tHey、Ps、Pc,并于15天、30天、90天行ESS和Barthel指数评分。结果与治疗前相比,治疗后两组患者血Till、PAl显著下降(P相似文献
108.
癌痛消胶囊调节小鼠荷H22移植性肝癌细胞VEGF表达的实验研究 总被引:5,自引:0,他引:5
目的 :通过观察癌痛消胶囊对小鼠荷H22 移植性肝癌细胞血管内皮细胞生长因子 (vascularendothelialgrowthfactor,VEGF)表达的调节作用 ,探讨该药抑制肿瘤的作用是否与抑制肿瘤血管生成有关。方法 :于昆明种雄性小鼠前肢右腋皮下接种0 2mlH22 肿瘤细胞悬液(浓度为1×107/ml)进行造模。利用造模动物观察瘤块重量 ,计算肿瘤生长抑制率 ,用免疫组化法检测瘤细胞中VEGF的表达程度。结果 :与阴性对照组相比 ,癌痛消胶囊组有明显的抑瘤作用(P<0 05) ,抑瘤率为36 34 % ;病理检测显示 ,造模各组VEGF阳性表达率为100% ,但程度不同 ,癌痛消胶囊组可使肿瘤组织VEGF的表达明显下调 ,与阴性对照组比较 ,差异有显著性意义(P<0 01)。结论 :癌痛消胶囊对小鼠荷H22 移植性肝癌细胞的生长有抑制作用 ,能减少血管生成调控基因VEGF的表达。 相似文献
109.
110.